Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Syndax Pharmaceuticals Q4 2025 Earnings Call - Two launches fuel $172M year, Revuforj NPM1 ramp and axatilimab IPF readout set the bar for 2026
Syndax closed 2025 as a commercial biotech in earnest, delivering $172.4 million in revenue driven by two launches. Revuforj generated $124.8 million in its first full year and accelerated in Q4 as th...
- Syndax reported $172.4 million total revenue in 2025, comprised of $124.8 million Revuforj net revenue, $42.4 million Niktimvo collaboration revenue, and $5.1 million milestones/royalties.
- Revuforj accelerated in Q4 with $44.2 million in net revenue, up 38% sequentially, and total prescriptions increased about 35% quarter over quarter.
- Approximately 1,050 patients have been treated commercially with Revuforj since launch, and Syndax estimates near 50% penetration of the KMT2A incident population within the first year.
- +12 more takeaways
Crinetics Pharmaceuticals Q4 2025 Earnings Call - PALSONIFY launch gains traction as company pivots to a commercial-stage endocrinology franchise
Crinetics closed 2025 as a commercial-stage company, with PALSONIFY driving an early U.S. launch while the pipeline advances. Q4 product revenue was $5.4 million, enrollment activity accelerated with ...
- PALSONIFY commercial launch underway: Q4 net product revenue of $5.4 million, contributing to Q4 total net revenue of $6.2 million and FY 2025 revenue of $7.7 million.
- Launch traction metrics: more than 200 enrollment forms in Q4 and prescriptions from over 125 unique prescribers across community and pituitary centers.
- Payer access early momentum: management reports formulary wins with several major plans, straightforward prior authorizations aligned to label language and no onerous step edits so far; medical exceptions being used for broader coverage.
- +11 more takeaways
PubMatic Q4 2025 Earnings Call - Agentic AI Leadership Sparks Inflection, Sets Stage for Double-Digit H2 2026 Growth
PubMatic says Q4 marked a structural inflection: revenue and adjusted EBITDA beat expectations, driven by CTV, mobile app, and rapidly scaling AI products. Management highlighted AgenticOS and Activat...
- Q4 and full-year 2025 marked an inflection: PubMatic beat guidance on revenue and adjusted EBITDA, reporting Q4 adjusted EBITDA of $27.8M, a 35% margin.
- Management repeatedly flagged agentic AI as the defining secular tailwind; AgenticOS and Agentic campaigns are core strategic differentiators being scaled.
- Agentic adoption: PubMatic has run over 250 agentic deals, launched an Agentic AI Accelerator with ~100 applicants, and reports early proof points including a 5x campaign cost efficiency.
- +13 more takeaways
Emergent BioSolutions Q4 2025 Earnings Call - Transformation Slashes Leverage to 1.9x as Adjusted EBITDA Hits $205M
Emergent spent 2025 executing a clear turnaround, trading revenue tailwinds for a leaner, more profitable company. Adjusted EBITDA rose to $205 million, gross margin expanded roughly 900 basis points,...
- Adjusted EBITDA rose to $205 million in 2025, a 12% year-over-year increase and above prior guidance.
- Net leverage improved to 1.9x at year-end 2025, down from 3.3x at December 2024 and 5.7x in Q1 2024.
- Year-end cash was $205 million, with total liquidity of $305 million including a $100 million undrawn revolver.
- +12 more takeaways
VTEX Q4 2025 Earnings Call - AI-driven productivity lifts margins as sales cycles elongate
VTEX says 2025 was a test but not a structural failure. Growth came in below long-term ambition, driven by tougher consumer markets in Brazil and Argentina, a promotional marketplace backdrop, and an ...
- Management frames 2025 slowdown as cyclical, not structural, blaming Brazil and Argentina macro weakness, promotional marketplace dynamics in Brazil, and an "AI wait and see" that lengthened decision cycles.
- Q4 GMV was $6.3 billion, up 17.2% year-over-year in USD and 10.0% FX-neutral; full-year GMV was $20.5 billion, up 12.1% USD and 12.9% FX-neutral.
- Q4 subscription revenue was $66.7 million, +12.2% year-over-year in USD and +5.4% FX-neutral; full-year subscription revenue was $234.9 million, +7.9% USD and +9.5% FX-neutral.
- +12 more takeaways
Progyny, Inc. Q4 2025 Earnings Call - Record 2025 Results and Push into Fully Insured Small-Group Market
Progyny closed 2025 with a clean, loud line: record revenue of $1.29 billion and adjusted EBITDA of $222 million, and they converted that into a record $210 million of operating cash flow. Management ...
- 2025 was a record year: $1.29 billion revenue and $222 million adjusted EBITDA, both double-digit improvements over 2024.
- Operating cash flow hit a record $210 million in 2025, up 17% year-over-year; company emphasizes high conversion of adjusted EBITDA to cash.
- Q4 and full-year results consistently beat prior guidance, with Q4 revenue above the top end of the range by about $11 million.
- +13 more takeaways
ICF Q4 2025 Earnings Call - Non-federal growth led by commercial energy to drive 2026 recovery
ICF closed 2025 with a clear inflection in its business mix, offsetting a 7.3% revenue decline with stronger margins and a big shift toward non-federal clients. Management guided to a return to revenu...
- Company delivered Q4 revenue of $443.7 million and full-year 2025 revenue of $1.87 billion, down 7.3% year over year but within guidance ranges.
- Management expects 2026 revenues of $1.89 billion to $1.96 billion, a roughly 3% midpoint increase, and non-GAAP EPS of $6.95 to $7.25, roughly 5% midpoint growth.
- Non-federal clients drove the rebound, with non-federal revenues up 14% in 2025 and expected to exceed 60% of total revenues in 2026.
- +11 more takeaways
Applied Optoelectronics Inc. Q4 2025 Earnings Call - 800G Ramp to Drive 2026 Growth, Capacity Not Demand
Applied Optoelectronics closed 2025 with record revenue of $456 million, driven by a big CATV recovery and a rapidly growing data center business. Management emphasized that the next phase is an 800G ...
- Record full-year 2025 revenue of $456 million, up 83% versus 2024; Q4 revenue was $134.3 million, in-line with guidance.
- Data center revenue for 2025 was $196 million, up 32% year-over-year; Q4 data center revenue was $74.9 million, up 69% year-over-year and 70% sequentially.
- CATV revenue nearly tripled to $245 million in 2025; Q4 CATV revenue was $54 million, down 24% sequentially from a record Q3 but in line with guidance.
- +12 more takeaways
Rocket Companies Q4 2025 Earnings Call - AI-driven integrations and Compass alliance turbocharge recapture and market-share gains
Rocket closed 2025 with a statement of scale, not a whisper. The company beat Q4 revenue guidance, delivered its highest fourth-quarter net rate lock volume and gain on sale margin since 2021, and pos...
- Q4 adjusted revenue was $2.44 billion, beating the top end of guidance by $140 million.
- CFO reported $42 billion in net rate lock volume for Q4, $36 billion excluding the correspondent channel, with a gain on sale margin of 320 basis points.
- Adjusted EBITDA rose to $592 million in Q4 from $349 million in Q3, expanding margin to 24% versus 20% in Q3.
- +15 more takeaways
Caris Life Sciences Q4 2025 Earnings Call - Achieve 1 interim validates Caris Detect launch and funds commercial and R&D expansion
Caris closed 2025 with a blowout quarter and a rare combination in this sector: rapid top-line growth and positive GAAP profitability. Q4 revenue jumped 125% year over year to $293 million, driven by ...
- Q4 2025 total revenue rose 125% year over year to $293.0 million, driven primarily by molecular profiling services at $282.0 million.
- Full year 2025 molecular profiling revenue grew 120% to $766.7 million, with total cases near 199,300 for the year and volume growth of about 22% year over year.
- Caris reported positive GAAP net income of $82 million in Q4 and adjusted EBITDA of $106 million for the quarter, with full year adjusted EBITDA of $138 million and free cash flow of $67 million for 2025.
- +12 more takeaways